CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
NSCLC
DRUG: CT-2103/carboplatin|DRUG: paclitaxel/carboplatin
Survival, up to 3 years post treatment
progression-free survival, disease control, clinical benefit, response rate, quality of life, and the safety, up to 3 years post treatment
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.